Literature DB >> 6132698

Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives.

D R Abernethy, D J Greenblatt, H R Ochs, D Weyers, M Divoll, J S Harmatz, R I Shader.   

Abstract

Women on low-dose estrogen oral contraceptives (OC) and drug-free control women matched for age, weight, and cigarette smoking habits, received single 2-mg IV doses of lorazepam or single 30-mg oral doses of oxazepam, two benzodiazepines metabolized by glucuronide conjugation. Kinetics were determined from multiple plasma concentrations measured during 48 hr after dosing. Mean kinetic variables for lorazepam in control and OC groups (n = 15 in each group) were: volume of distribution (Vd), 1.33 and 1.45 l/kg; elimination t1/2, 13.1 and 12.2 hr; total clearance, 1.25 and 1.50 ml/min/kg; free fraction in plasma, 10.3% and 10.3% unbound. For oxazepam, kinetic variables in the two groups (n = 14 and 17) were: Vd, 1.05 and 1.19 l/kg; t1/2, 7.6 and 7.2 hr; total clearance, 1.60 and 2.03 ml/min/kg; free fraction, 4.6% and 4.9% unbound. None of these differences were significant. Thus, metabolic clearance by glucuronidation of lorazepam and oxazepam is not significantly affected by OC, in contrast with the highly significant reduction in clearance of the oxidized benzodiazepine diazepam.

Entities:  

Keywords:  Age Factors; Body Weight; Contraception; Contraceptive Agents; Contraceptive Agents, Female; Contraceptive Methods--pharmacodynamics; Control Groups; Drugs; Ethinyl Estradiol; Examinations And Diagnoses; Family Planning; Laboratory Examinations And Diagnoses; Laboratory Procedures; Metabolic Effects; Oral Contraceptives, Low-dose--pharmacodynamics; Oral Contraceptives--pharmacodynamics; Reproductive Control Agents; Research Methodology; Smoking; Treatment

Mesh:

Substances:

Year:  1983        PMID: 6132698     DOI: 10.1038/clpt.1983.85

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  13 in total

Review 1.  Pharmacokinetic drug interactions with oral contraceptives.

Authors:  D J Back; M L Orme
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

2.  Lack of impairment of fluocortolone disposition in oral contraceptive users.

Authors:  U F Legler
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 3.  Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach.

Authors:  Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives.

Authors:  D R Abernethy; E L Todd
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 5.  Benzodiazepine poisoning. Clinical and pharmacological considerations and treatment.

Authors:  P Gaudreault; J Guay; R L Thivierge; I Verdy
Journal:  Drug Saf       Date:  1991 Jul-Aug       Impact factor: 5.606

6.  Sex-difference and the effects of smoking and oral contraceptive steroids on the kinetics of diflunisal.

Authors:  J I Macdonald; R J Herman; R K Verbeeck
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

7.  Gender and oral contraceptive steroids as determinants of drug glucuronidation: effects on clofibric acid elimination.

Authors:  J O Miners; R A Robson; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1984-08       Impact factor: 4.335

Review 8.  Oral contraceptives. Are drug interactions of clinical significance?

Authors:  G M Shenfield
Journal:  Drug Saf       Date:  1993-07       Impact factor: 5.606

9.  Interaction of propoxyphene with diazepam, alprazolam and lorazepam.

Authors:  D R Abernethy; D J Greenblatt; D S Morse; R I Shader
Journal:  Br J Clin Pharmacol       Date:  1985-01       Impact factor: 4.335

10.  Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion.

Authors:  Xi He; Leah M Hesse; Suwagmani Hazarika; Gina Masse; Jerold S Harmatz; David J Greenblatt; Michael H Court
Journal:  Br J Clin Pharmacol       Date:  2009-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.